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Low Concentration of Sodium 
Butyrate from Ultrabraid+NaBu 
suture, Promotes Angiogenesis 
and Tissue Remodelling in Tendon-
bones Injury
Donghui Liu1, Silvia Passos Andrade2, Pollyana Ribeiro Castro2, John Treacy3, 
Jason Ashworth1 & Mark Slevin1,4
Sodium butyrate (NaBu), a form of short-chain fatty acid (SCFA), acts classically as a potent anti-
angiogenic agent in tumour angiogenesis models, some authors demonstrated that low concentrations 
of NaBu may contribute to healing of tendon-bone injury in part at least through promotion of tissue 
remodelling. Here, we investigated the effects of low-range concentrations of NaBu using in vitro 
and in vivo assays using angiogenesis as the primary outcome measure and the mechanisms through 
which it acts. We demonstrated that NaBu, alone or perfused from the UltraBraid+NaBu suture 
was pro-angiogenic at very low-range doses promoting migration, tube formation and cell invasion 
in bovine aortic endothelial cells (BAECs). Furthermore, cell exposure to low NaBu concentrations 
increased expression of proteins involved in angiogenic cell signalling, including p-PKCβ1, p-FAK, 
p-ERK1/2, p-NFκβ, p-PLCγ1 and p-VEGFR2. In addition, inhibitors of both VEGFR2 and PKCβ1 blocked 
the angiogenic response. In in vivo assays, low concentrations of NaBu induced neovascularization 
in sponge implants in mice, evidenced by increased numbers of vessels and haemoglobin content 
in these implants. The findings in this study indicate that low concentrations of NaBu could be an 
important compound to stimulate angiogenesis at a site where vasculature is deficient and healing is 
compromised.
Sodium butyrate (NaBu), a form of short-chain fatty acid (SCFA), has been reported to exert profoundly effects 
on mammalian cells in vitro and modify the activity of many types of cells1,2, such as colorectal cancer cells3–5. It 
has been shown to inhibit angiogenesis at high concentrations. It is recognized to serve as a major energy sub-
strate for colonocytes, exert potent effects on epithelial cells, induce cell replication and proliferation, act as an 
inducer or inhibitor of cell differentiation, induce apoptosis6–9, and lead to cell growth arrest or cell death10,11. It 
can also modify cell morphology, possibly through its effects on the cytoskeleton1,2,12. Many biological properties 
of NaBu are well documented; for example, it can inhibit oral cancer cell growth by arresting the cell cycle in G1 
phase13, whilst, others have demonstrated that NaBu exerts a strong permissive effect on hepatocyte in vitro14. 
Normal tissue physiological concentrations of sodium butyrate are between 0.1–0.5 ug/cm3 far below the normal 
experimental range used in cell culture studies (Meijer et al.15).
Significant work has reported that high concentrations NaBu may inhibit histone deacetylase, which results in 
hyperacetylation of proteins inhibiting DNA replication2,16. NaBu promotes hyperphosphorylation of the nuclear 
proteins HMG 14 and HMG 1717,18 which are associated with active chromatin. Thus, it is believed that the 
nucleus is the essential cell compartment which NaBu acts upon19,20, while, the effects of NaBu on gene/protein 
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expression in the non-epithelial cell populations, including the microvascular endothelial cells, are presently 
unknown.
To our knowledge, there are currently no reports on the biological functions of low- range concentrations of 
NaBu within vascular cells.
Recently, some reports have described the effects of NaBu on the tendon-bones injury repair and remodel-
ling21,22. It was shown that UltraBraid suture typically used in the therapy of tendon-bones injury, when impreg-
nated with NaBu enhanced vascular repair and remodelling in a rabbit model (now undergoing clinical trials), 
suggesting NaBu may promote local tissue remodelling in tendon-bones injury improving strength and healing.
The Ultrabraid+NaBu suture promotes tendon-bones injury repair and remodelling, with evidence of 
increased angiogenesis, a short healing time and better clinical outcomes22. Hence, here, we aimed to investigate 
the mechanisms through which NaBu enhances tendon-bones injury via modulation of angiogenesis.
In relation to this, moderate levels of NaBu was shown to down-regulate the expression of vascular endothe-
lial growth factor (VEGF) by affecting the activation of HIF-1α , a key regulator of VEGF on Caco-2 cells, by 
down-regulating the expression of nuclear HIF-1α 23–26, HIF-1α expression can be regulated through several 
post-transcriptional mechanisms. In addition, NaBu has been shown to modulate the activity of nuclear tran-
scription factor-kappa beta (NF-κ β ) in a number of different cell types, including colon cancer cells23. Hence, the 
anti-proliferative effect of NaBu on transformed cells is well established, and NaBu has emerged as an antiangi-
ogenic agent that directly represses the expression of angiogenic ligands or indirectly interferes with endothelial 
cell proliferation/enzymes required for angiogenesis27–29.
In this study, the mechanisms through which NaBu modulates angiogenesis at low concentrations have been 
examined and their possible relationship to enhance repaired of tendon-bone injury via the Ultrabraid + NaBu 
suture discussed.
Materials and Methods
Materials. Collagen and gelatine were purchased from Sigma Aldrich UK. The Sutures and NaBu were kindly 
provided by Smith & Nephew Inc, USA. MatrigelTM gel was purchased from BD Biosciences International, UK. 
Foetal bovine serums (FBS), trypsin, phosphate buffered saline (PBS) and Dulbecco’s Modified Eagle’s Medium 
(DMEM) were purchased from Lonza, UK.
Cell culture. Bovine aortic endothelial cells (BAECs) were prepared as described by Sattar et al.30. BAECs were 
cultured in DMEM supplemented with 10% FBS, 2 mM glutamine and 1% antibiotics (100 U/ml penicillin and 
100 μ g/ml streptomycin) in T25 flask pre-coated with 0.1% gelatin and incubated in a water-saturated, 5% CO2 
incubator at 37 °C. For each experiment, BAECs were serum starved (incubated with DMEM supplied with 1% 
FBS) for 24 hours prior to the assay. Generally, about 80% confluent BAECs incubated in serum poor medium 
(SPM, contains 1% FBS) overnight and up to 24 hours. NaBu at low-range concentrations (1 ng/ml, 5 ng/ml, 
10 ng/ml, 25 ng/ml, 50 ng/ml, 0.1 μ g/ml, 1.0 μ g/ml, 5.0 μ g/ml, 10.0 μ g/ml, 25 μ g/ml, 50.0 μ g/ml and 100.0 μ g/ml) 
were investigated in the study. All experiments were repeated three times and samples were prepared in triplicate 
(n = 9) in all cases. The BAECs were used between passages 5–10 for all the experiments.
In vitro studies. Endothelial cell tube formation assay. BAEC were cultured in complete growth medium 
(DMEM with 10% FBS) in a water-saturated incubator at 37 °C and 5% CO2. When cells reached at about 80% 
confluence, the growth medium was changed to SPM containing only 1% FBS and incubated for a further 
24 hours. Cells were trypsinised (10% trypsin-EDTA solution) and re-suspended at 1 × 106 cells/ml. Cells were 
mixed thoroughly with an equal volume of liquified MatrigelTM gel, together with NaBu at variety of low-range 
concentrations (as described previously). The cell/MatrigelTM gel mixture was put into 48-well plate and left for 
1 hour to allow the MatrigelTM gel to polymerize at 37 °C. The NaBu-impregnated MatrigelTM gel/cell samples 
were incubated in SPM for 24 hours. Fibroblast growth factor-2 (FGF-2) at concentration of 25 ng/ml was used as 
positive control in place of NaBu. After 24 hours incubation, cells were fixed with 50 μ l/well of 4% paraformalde-
hyde (PFA) for 15 minutes at room temperature (RT). Tube formation in each well was assessed by phase contrast 
microscopy and images were taken using a digital camera (Zeiss).
Endothelial cell migration assay. BAECs were cultured on 1 mm × 1 mm glass cover slips in complete 
growth media and incubated in a water-saturated incubator at 37 °C and 5% CO2. When cells reached about 80% 
confluence, the growth medium was replaced with SPM and incubated for further 24 hours. Adherent cells were 
then scratched in one single continuous line across the glass cover slip using a razor blade and then washed twice 
with warm PBS. Cells were then incubated in SPM containing NaBu at a various of low-range concentrations (as 
described previously) and incubated for further 24 hours. Again, FGF-2 (at 25 ng/ml) was used as positive control. 
Cell migration was assessed by phase contrast microscopy and images were taken using a digital camera (Zeiss). 
Both migration distance and number of migrated cells were measured.
Endothelial cell invasion assay. BAECs migration and tube formation were also enhanced by NaBu in the 
sandwich MatrigelTM gel, suggesting a neoangiogenic effect at low-range concentrations of NaBu. NaBu-induced 
ECs tube formation and invasion assay was performed using two layers of sandwiched MatrigelTM gel. BAECs 
were mixed with MatrigelTM gel as previously described and cultured for 24 hours at 37 °C and 5% CO2 to enable 
tube-like structures to form. A second layer of MatrigelTM gel, containing various low-range concentrations (as 
described previously) of NaBu, was applied in direct contact with the first layer of MatrigelTM gel. After further 
24 hours incubation, cells were fixed with 50 μ l/well of 4% PFA for 15 minutes at RT. ECs tube formation and inva-
sion were assessed by using phase contrast microscopy and images were captured using a digital camera (Zeiss).
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Ultrabraid+NaBu suture induced endothelial cell tube formation assay. BAEC were cultured in 
complete growth medium in a water-saturated incubator at 5% CO2 and 37 °C. When cells reached about 80% 
confluence, the growth medium was replaced with SPM and incubated for a further 24 hours. Cells were tryp-
inised and re-suspended at 2 × 106 cells/ml in complete media before adding 4 × 105 cells onto pre-polymerized 
MatrigelTM gel in a 24-well plate. The plate was then incubated for 4 hours at 5% CO2 and 37 °C to enable cells to 
attach to the MatrigelTM gel. After checking for adhesion to the first layer of MatrigelTM gel, the media was aspirated 
from each well and a NaBu-impregnated ultrabraid suture was applied to the middle of each well. Immediately 
a second layer of MatrigelTM gel was added onto the first layer of the MatrigelTM gel to form a MatrigelTM gel 
sandwich and allowed to polymerize for 1 hour at 37 °C. The MatrigelTM gel sandwich was incubated for 24 hours 
at 37 °C and 5% CO2 following the addition of 500 μ l low serum (1% FBS) growth medium per well. A general 
surgical suture was used as described above as a control in place of the impregnated ultrabraid suture.
Measurement of suture release kinetics of sodium butyrate. 6-well plates were used to incorporate 
various lengths of suture within a MatrigelTM gel tube-formation protocol system and with and without BAECs. 
Following insertion and incubation of the plates at 37 °C and 5% CO2, 3 mm Strips of MatrigelTM gel were accu-
rately cut on each side of the suture using a scalpel at time zero, 4 h and 24 h (n = 5 per test). Control liquefied 
MatrigelTM gel + /− butyrate concentration range (spiked) was used to construct a standard curve.
The matrix was liquefied with 1.5 U/ml dispase I and the reaction stopped using 5 mM EDTA. The MatrigelTM 
gel + dispase I - was spiked with different concentrations of butyrate 0.01 micrograms-100 micrograms-pilot 
tested and quantified by a standard HPLC protocol.
Kinexus phopho-protein microarray analysis. BAECs were seeded in completed medium in a 6-well 
plate at a cell concentration of 2.5 × 105 cells/ml/well. After 48 hours incubation, the growth medium was replaced 
with SPM and incubated a further 24 hours. The following day, 1 μ g/ml of NaBu was added to each well and 
allowed to incubation at 37 °C and 5% CO2 for 10 minutes and 1 hour respectively. To inspect the variation of the 
signalling protein expression induced by the NaBu, the phosphor-protein microarray of 880 phopho-site proteins, 
KinexusTM Antibody Microarray (KAM)-1.2 was performed by Kinexus Bioinformatics (Vancouver, Canada).
Proteins from NaBu-stimulated and un-stimulated cells were extracted according to Kinexus service proto-
cols. Briefly, cells were washed twice with cold PBS, then protein was extracted using a kinexus cell lysis buffer 
which was previously described31. Cell extracts were then collected and sonicated three times for 15 seconds, and 
protein concentrations were measured by the Bradford protein assay using a spectrophotometer and according to 
the manufacturer’s instructions (Bio-rad, Munchen, Germany). For each sample, protein (200 μ g in 100 μ l) was 
transferred to a fresh 1.5 ml Eppendorf screw cap and then was sent to Kinexus for analysis.
Western blot Analysis. Whole cell lysates were solubilized in a 2-fold concentrated sample buffer, and 
30 μ g of total protein sample were separated by SDS-PAGE. Proteins were transferred to a nitrocellulose membrane 
(Whatman, protran BA85, Germany), probed with appropriate primary antibodies (Abcam) as indicated and incu-
bated over-night at 4 °C. Membranes were then incubated with an HRP IgG secondary antibody. Bound HRP IgG 
was visualized using enhanced chemi-luminescence (ECL, Thermo scientific, UK) with Western Blotting Substrate. 
Excess liquid was absorbed and the membrane exposed to ChemiDoc Touch Imaging System (Bio-rad, UK). 
Band intensity was quantified with Image-Lab software (supplied by ChemiDoc Touch Image System, Bio-rad, 
UK). The fold increase of each specific protein was determined by the ratio of band intensities of treated and 
untreated cells, normalized to loading control (α -tubulin, Abcam).
BAECs were seeded in complete medium in a 6-well plate at a cell concentration of 2.5 × 105/ml/well. After 
48 hours incubation, the medium was replaced with SPM and cells incubated for a further 24 hours. Next, 
1 μ g/ml NaBu was added and the cells incubated for 10 min, 20 min, 30 min and 1 hour at 37 °C. In addition, 
BAECs cultured under the same conditions were exposed to PKC inhibitor (Ruboxistaurin, optimised and 
used at 0.2 nM-see Kunt et al. for information of the high specificity of this inhibitor)32 for 4 hours and 24 hours 
respectively prior to addition of NaBu (1 μ g/ml) in some experiments in order to identify any potential blocking 
effects on PKC signalling. In addition, m-CRP protein was applied to the assay (as an alternative positive control 
expected to show a lack of inhibition with the PKC inhibitor since its signalling does not pass through this path-
way). Briefly, the starved BAECs were incubated + /− PKC inhibitor (Ruboxistaurin, 0.2 nM) for 4 hours, then 
5 μ g/ml of m-CRP protein was introduced to the cells for 10 minutes, untreated cells were as control, and m-CRP 
treated cells (without inhibitor) were used as a positive control. The same method was used as for the VEGFR 
inhibition assay which was as follows: BAECs were pre-incubated with VEGFR receptor blocker (1:100 dilution) 
for 4 hours, then the cells were treated with NaBu (1 μ g/ml) for 20 min. FGF-2 (25 ng/ml) was as positive control. 
After rapid washing with ice-cold PBS, cells were lysed with 200 μ l/well of ice-cold radioimmunoprecipitation 
(RIPA) buffer (pH 7.5) containing 25 mM Tris-HCl, 150 mM NaCl, 0.5% sodium deoxycholate, 0.5% SDS, 1 mM 
EDTA, 1 mM sodium orthovanadate (EGTA), 1 mM phenylmethylsulfonyl fluoride (PMSF), 1% Triton × 100 
and 1 μ M leupeptin. The protein concentration of cell lysates was determined using the Bradford protein assay 
(Bio-rad, Munchen, Germany) and equal quantities of proteins (30 μ g) were mixed with 2× Laemmli sample 
buffer, boiled in a water bath for 15 min then centrifuged. Samples were separated along with pre-stained molecular 
weight markers (32,000–200,000 kDa) by 12% SDS-PAGE. Proteins were electro-transferred (Hoefer, Bucks, UK) 
onto nitrocellulose filters (1 h) and the filters were blocked for 1 h at room temperature in TBS-Tween 
(pH 7.4) containing 1% bovine serum albumin (BSA). Filters were stained with the primary antibodies diluted 
in the blocking buffer, overnight at 4 °C on a rotating shaker. The following primary antibodies (1:1000) from 
Abcam (Abcam, UK), p-ERK1/2 (S404), p-FAK, p-NFκ β , p-PKCβ 1, p-PLCγ 1 and p-VEGFR2 were applied. After 
washing (5 × 10 min in TBS-Tween at room temperature), filters were stained with either goat anti-rabbit or 
rabbit anti-mouse HRP-conjugated secondary antibodies diluted in TBS-Tween containing 5% de-fatted milk 
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(1:2000, 1 h, room temperature) with continuous mixing. After a further five washes in TBS-Tween, proteins were 
visualized using enhanced chemi-luminescent detection (ECL, Thermo scientific, UK) and semi-quantitatively 
identified fold differences compared with house-keeping controls determined using Image-Lab software. All 
experiments were repeated at least twice and a representative example is shown.
In vivo study. Animal Ethics Statement. The use of animals and procedures for this study was approved by 
the Ethics Committee in Animal Experimentation (CETEA) of Federal University of Minas Gerais (Protocol no. 
267/ 2014). All surgery was performed under ketamine and xylazine anesthesia, and all precautions were made 
to minimize suffering.
Animals. A total number of 104, eight-weeks-old male C57/Bl mice from Centro de Bioterismo of the Federal 
University of Minas Gerais (UFMG) were used. The study design, replicates per test and total animal numbers 
used are shown in Table 1. Mice were maintained in individual cages with food and water ad libitum, with con-
trolled temperature and humidity in the animal house at the Department of General Pathology, Institute of 
Biological Sciences. Experiments were carried out in accordance with approved procedures granted by the Ethics 
Committee in Animal Experimentation of UFMG. All animal care and procedures were approved (protocol num-
ber 43/2014) and complied with the guidelines established by the Institutional Committee on Animal Welfare 
(CETEA) of Federal University of Minas Gerais. Efforts were made to avoid all unnecessary distress to animals.
The light/dark cycle was 12:12 h with lights on at 7:00 am and lights off at 7:00 pm. Post-operatively, animals 
were monitored for any signs of infection at the operative site.
All tests were carried out in a double-blinded fashion and details of methodology are given below.
Statistical evaluation. All statistical tests were performed using SPSS. A total of 64 animals were used for 
the implant experiments (n = 8 per group, total = 64 animals) based on advice from an independent medical stat-
istician together with information gathered from protocol developers in respect of minimum numbers required 
to gather statistically significant data. This advice took into account possible mortality (n = 0–1 per group) and 
incorrect implant (n = 0–1 per group), with statistical significance being tolerable at n > 5 per group based on 
our previous studies33. For histology, based on our previous experience a minimum of n = 5/group (total n = 40 
animals) was sufficient to give statistical significance in ANOVA tests when comparing treated groups with the 
control group. Furthermore, based on previous statistical analysis, we have established that counting 5 micro-
scopic fields (8533 μ m2 per field) per treatment group was sufficient to maintain the standard deviation within a 
10% variation34.
Implant Methodology. C57/Bl mice (n = 20 per test) were implanted with sponge disks containing NaBu 
(0.1–100 μ g NABU in 40 μ l followed by 2 additional doses at 48 hours and 76 hours) or with NaBu-impregnated 
Ultrabraid sutures. A sub-cutaneous dorsal pouch was prepared for implant deliveries. After 7 days, implants 
were assessed for haemoglobin content using the Drabkins method. In addition, homogenised supernatants from 
implants after 7 days incubation were evaluated for N-acetyl-β -D-glucosaminidase (NAG) determination of 
mononuclear cells infiltration, VEGF expression and histology.
Implantation of the sponge discs. Mice were anesthetized (i.p.) with a mixture of xylazine (10 mg/kg) 
and ketamine hydrochloride (100 mg/kg). Their dorsal hair was shaved and the skin wiped with 70% ethanol. A 
sponge disk made of polyether polyurethane (dimensions = 8 mm diameter, 4 mm thick, volume 0.2 cm3) was 
then aseptically inserted into a subcutaneous pouch made with curved artery forceps through a 1cm long dor-
sal mid-line incision (treated groups). After the implantation procedure, the animals received the first dose of 
sodium butyrate (0.1 μ g, 0.5 μ g, 1.0 μ g 5.0 μ g, 10.0 μ g, 50.0 μ g and 100 μ g respectively in 40 μ l) or phosphate buff-
ered saline (PBS) as control. Additional doses were given at 48 hours and 96 hours post-implantation (following 
pilot studies using single, double and multiple doses and consideration of the 24–47 hour butyrate metabolism 
kinetic to ensure replenishment throughout the experiment and maintenance of concentration levels).
NaBu total dose (μg)
Test and Replicate Number
Haemoglobin (Hb) N-acetyl-β-D-








0 (Control) 8 5
Total animals 64 40
Table 1.  Animal study design, tests performed and number of animals (replicates) per test.
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At 7 days post-implantation, the animals were sacrificed and implants removed for assessment of haemoglobin 
content (vascular index), inflammatory marker (N-acetyl-β -D-glucosaminidase, NAG) and VEGF levels. For 
histological analysis, a separate group of mice (n = 5 for each group) was used.
Angiogenesis Quantitation. For histology, the sponge implants from all groups (n = 5 for each group) 
were fixed in 10% buffered formalin (pH 7.4) and processed for paraffin embedding. Sections 5 μ m thick were 
stained with haematoxylin/eosin (H&E) and processed for light microscopy. To perform morphometric analysis 
of a number of new blood vessels that had vascularised the sponge, images of cross sections obtained from 5 
fields of view were captured for each implant with a planapochromatic objective (40x) in light microscopy (final 
magnification = 400x). Images were digitized through a JVC TK-1270/JCB microcamera and transferred to an 
analyzer (software: Image-Pro Plus 4.5, Media Cybernetics, Inc.). For statistical analysis, a countable blood vessel 
was defined as a tube-like structure with a lumen, whether or not it contained red blood cells.
Haemoglobin Analysis. The extent of the vascularization of the sponge discs was assessed based on the 
amount of haemoglobin (Hb) detected in the tissue using the Drabkin method. At 7 days post-implantation, ani-
mals in both treated and untreated groups were euthanized and the sponge discs carefully removed. Sponges were 
dissected from adherent tissue, weighed, homogenized (Tekmar TR-10, OH) in 2 mL of Drabkin reagent (Labtest, 
São Paulo, Brazil) and centrifuged at 4 °C at 12,000 g for 20 min. The supernatants were then filtered through a 
0.22 μ m Millipore filter. The Hb concentration of the samples was determined spectrophotometrically by meas-
uring absorbance at 540 nm using a colourimetric plate reader and compared against a standard curve of Hb. The 
content of Hb in the sponge discs was expressed in micrograms of Hb per milligram of wet tissue.
VEGF analysis. Implants from control or treated groups were removed at day 7 post-implantation, homog-
enized in PBS pH 7.4 containing 0.05% Tween-20 (Difco/USA) and centrifuged at 4 °C, 10,000 × g for 30 min. 
VEGF in the supernatant from each sample was measured using an immunoassay kit (R&D Systems, USA) 
according to the manufacturer’s protocol. Briefly, dilutions of cell-free supernatants were added in duplicate to 
wells of the assay plate that was coated with a murine monoclonal antibody against VEGF, followed by the addition 
of a second horseradish peroxidase-conjugated polyclonal antibody against VEGF. After washing to remove any 
unbound antibody-enzyme reagent, a substrate solution of tetramethylbenzidine (TMB, Sigma-USA) was added 
to the wells. The colour development was stopped, after 20 min incubation, with sulphuric acid and the absorb-
ance measured at 450 nm on a spectrophotometer (Thermoplate Tekmar). The VEGF concentration (pg/ml) 
in each sample well was determined by interpolation from a set of recombinant murine VEGF standards provided 
in the kit. VEGF concentration from implants was then expressed as pg VEGF per mg wet tissue.
Measurement of NAG (N-acetyl-β-D-glicosaminidase). The infiltration of mononuclear cells was 
quantitated by measuring the levels of the lysosomal enzyme N-acetyl-β -D-glucosaminidase (NAG) present 
in high levels in activated macrophages. Following the Hb measurements the remaining pellets were weighed, 
homogenized in sodium chloride (NaCl) solution (0.9% w/v) containing 0.1% v/v Triton X-100 (Promega; USA) 
and centrifuged (3,000 × g; 10 min at 4 °C). Supernatants were incubated for 30 min with an equal volume of 
2.24 mM p-nitrophenyl-N-acetyl-beta-D-glucosaminide (Sigma; USA) prepared in citrate/sodium phosphate 
buffer (0.1 M citric acid, 0.1 M Na2HPO4; pH4.5). The reaction was stopped by the addition of glycine buffer 
(0.8 M glycine, 0.8 M NaCl, 0.8 M NaOH; pH 10.6). Hydrolysis of the substrate was determined by measuring the 
absorbance at 400 nm. NAG activity was expressed as nmol of p-nitrophenol per mg wet tissue.
Results
Nanogram concentrations of sodium butyrate induced angiogenesis in vascular endothelial 
cells. In vitro testing showed that addition of sodium butyrate between 25 ng/ml and 1ug/ml to BAECs in 
MatrigelTM gel caused a significant increase in tube-like-structure formation (Fig. 1). Similar effects were seen 
in wound recovery using a scratch wound method, where sodium butyrate was effective at 100 ng/ml to 1 ug/ml 
(Fig. 2). A cell invasion assay was performed also in MatrigelTM gel, where a second outside layer containing sodium 
butyrate was placed around the already formed tube-like structures. Sodium butyrate from 25 ng/ml to 10 ug/ml was 
able to significantly increase the invasion of cells and tubes into this second layer over a further 24 h period (Fig. 3).
Ultrabraid+NaBu suture stimulated tube-like-structure formation of BAECs in matrigel. 
Straight lengths of the suture were placed in 6-well plates within MatrigelTM gel and all other parameters were the 
same as per the standard MatrigelTM gel assay. Normal suture did not stimulate tube formation, however, the 
UltraBraid + NaBu suture induced notable tube formation within the first 3–6 mm around the suture, and a lesser 
stimulatory effect from 9–12 mm (Fig. 4). In order to define if butyrate released from the suture was responsible for this, 
we measured butyrate levels in each 3 mm strip using HPLC and the data showed that significant quantities of butyrate 
were found after 24 h within the first 6 mm of MatrigelTM gel (approximately 16–12 and 8–6 μ g/ml in the first and 
second 0033 mm slices respectively, over a period of 24 h; without and in the presence of BAEC respectively) (Fig. 4B).
Butyrate induced angiogenic cell signalling in BAECs through VEGFR2 and PKCβ1. A targeted 
Kinexus phospho-protein microarray employing stringently validated antibodies to over 500 target proteins 
and duplicate fields, was performed where BAEC were exposed to sodium butyrate (1 μ g/ml/8 minutes and 1 h) 
and compared with control cells. Using their software packages where normalised signals use 100%CFC cor-
responding to a 2-fold increase, increases in phosphorylation of VEGFR2, PKCβ 1, FAK, ERK1/2, NFκ β were 
seen within 8 minutes (Fig. 5A; Kinexus raw data included as Supplementary data-1). Western blotting con-
firmed these results showing strong up-regulation of phosphorylated proteins in treated cell lysates ranging from 
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10–60 minutes exposure (Fig. 5C). Figure 5B,D show fold differences in protein expression measured by image J 
compared to control expression (1.0).
Inhibitor cell signalling blocking studies. Inhibitors of PKCβ 1 (ruboxistaurin, optimised to 0.2 μ M in 
our unpublished pilot studies) and/or VEGFR2 (blocking antibody; Millipore; ABS553) blocked protein/receptor 
phosphorylation respectively (Fig. 6E,G,I). Both VEGFR2 inhibition and PKCβ 1 blocking, inhibited subsequent 
tube-like-structure formation in matrigel (Fig. 6A,C). As a positive control, FGF-2 tube-like structure formation 
and signalling were not affected when using the VEGFR inhibitor, demonstrating a level of specificity of the 
inhibitors. In addition, mitogenic signalling of another positive control protein (mCRP), through p-ERK 1/2 
Figure 1. Low dose NaBu induced BAEC tube formation. The bar graph (A) indicates that NaBu induced 
BAEC cells tube formation start from 25 ng/ml, with maximal effects at concentrations of 0.1–1.0 μ g/ml Higher 
concentrations had less effect, and those of 10.0, 25.0, 100.0 μ g/ml, showed no significant differences compared 
to the control. The images (B) shows that there were significantly more tube-liked structures when NaBu 
concentrations were between 0.1 μ g/ml (B5) and 1 μ g/ml (B6). B1: Control, B2: FGF-2, B3: NaBu 1 ng/ml, B4: 
NaBu 25 ng/ml, B5: NaBu 0.1 μ g/ml, B6: NaBu 1 μ g/ml, B7: NaBu 25 μ g/ml, B8: NaBu 100 μ g/ml. All experiment 
were repeated at least twice and representative examples are shown.
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was also not affected by the inhibitor demonstrating the selectivity of our inhibitor at the concentrations used 
(Fig. 6G). Figure 6F,H,J show fold differences in protein expression measured by image J compared to control 
expression (1.0).
In vivo subcutaneous implants of sodium butyrate elicited a pro-angiogenic phenotype. Using 
the sponge implant model (mouse), we showed that sodium butyrate soaked sponges (0.1–1.0 μ g/ml) demon-
strated a notable increase in Hb influx (Fig. 7A,B,D), and the number of new microvessels within the matrix 
measured after 7 days (there were no vessels in the sponge vicinity at the start of the experiment) (Fig. 7C), 
although levels of VEGF were not found to be elevated (data not included).
Discussion
It is generally reported that NaBu is an inhibitor of histone deacetylases (HDACs)35–37, and this inhibition has 
been utilised in relation to cancer; however, from a vascular perspective at high concentrations (> 500 μ g/ml) 
butyrate inhibited VEGF production by glioblastoma cells28, The most recent paper in this area by Kim and 
Chuang38 found a similar result to ours in that NaBu protected against ischaemia-induced injury in a rat model-in 
part at least through up-regulation of VEGF protein. From our phospho-screening results, at the pro-angiogenic 
concentrations tested, only PKC could be linked an HDACs signalling network through GPCR/TRPC and 
we suggest here that at these very low concentrations (0.1–1.0 μ g/ml), HDAC pathways were not significantly 
modulated.
Figure 2. Sodium butyrate induced BAEC cell migration. BAECs treated with NaBu at very low 
concentrations stimulated BAEC cell migration. FGF-2 at 25 ng/ml was the positive control. The bar chart  
(A) shows that NaBu induced BAEC cells migration substantially at concentrations of 0.1 μ g/ml–1.0 μ g/ml but 
there were no significance with concentrations of 5.0 μ g/ml and above. The representative images (B) show that 
there were more migrated cells at NaBu concentrations of 0.1 μ g/ml (B5) and 1 μ g/ml (B6). B1: Control, B2: 
FGF-2, B3: NaBu 1 ng/ml, B4: 2% NaBu 25 ng/ml, B5: NaBu 0.1 μ g/ml, B6: NaBu 1 μ g/ml, B7: NaBu 25 μ g/ml, 
B8: NaBu 100 μ g/ml. All experiment were repeated at least twice and representative examples are shown.
www.nature.com/scientificreports/
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Several studies have shown and defined that NaBu acts classically as a potent anti-angiogenic agent in tumour 
angiogenesis models in vivo and in vitro13,27,39. However, previously published evidence by our consortium estab-
lished a potentially beneficial effect of UltraBraid+NaBu in a rabbit -bone healing model with evidence of posi-
tive tissue remodelling and local angiogenesis40. Therefore, here, we evaluated the possible pro-angiogenic effects 
of NaBu in vitro and in an inflammatory angiogenesis model induced by sponge implants in mice.
Of primary importance initially, was to determine the relative release rate of butyrate from the 
UltraBrade+NaBu suture to indicate the likely micro-environmental concentrations cells and tissues would be 
exposed to in vivo. We showed that sodium butyrate release from the suture into MatrigelTM gel ECM was in the 
order of magnitude of 5–10 μ g/ml over a 24 h period diffusing up to around 1cm or more from the suture-and 
being an order of magnitude greater than normal tissue concentrations of butyrate15. Taking into account the 
kinetics of NaBu metabolism, we estimated a micro-environmental dynamic expression of between 0.1–1.0 μ g/ml 
Figure 3. Sodium butyrate induced BAEC cell invasion. Sodium butyrate was introduced to the second layer 
of growth factor reduced Matrigel at various concentrations and incubated in 2% FBS DMEM medium at 37 °C 
for 24 hours, the cells without NaBu were used as negative control and FGF-2 at 25 ng/ml was a positive control. 
The bar chart (A) shows that NaBu induced BAEC cells to invade into the second layer of Matrigel, and the cell 
invasion effects were seen at concentrations 25 ng/ml–1.0 μ g/ml, (B) The representative images show tube-like 
structures in a second layer of matrigel at 0.1 μ g/ml (B5) and 1 μ g/ml (B6). B1: Control, B2: FGF-2, B3: NaBu 
1 ng/ml, B4: 2% NaBu 25 ng/ml, B5: NaBu 0.1 μ g/ml, B6: NaBu 1 μ g/ml, B7: NaBu 25 μ g/ml, B8: NaBu 100 μ g/ml. 
All experiment were repeated at least twice and representative examples are shown.
www.nature.com/scientificreports/
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Figure 4. Ultrabraid (NaBu-infused) suture induced tube formation. Sodium butyrate Ultrabraid suture 
was introduced to the sandwich Matrigel, and the cells were seeded at 1,000,000/ml and incubated in 2% FBS 
DMEM medium at 37 °C for 24 hours. BAEC cells with general (none-NaBu containing) suture, and cells 
without suture were used as negative control and FGF-2 at 25 ng/ml was a positive control, and cells incubated 
in 10% FBS DMEM medium were also used as a secondary positive control. The bar chart (A) shows Ultrabraid 
suture significantly induced BAEC tube formation (blue bar), compared to the general suture (orange bar).  
(B) Representative images showing tube-liked structures within the 3 mm (B5) up to 9 mm (B7) regions. B1: The 
first 3 mm strip of Matrigel from general suture for the control, B2: Second 3 mm strip of Matrigel from general 
suture, B3: third 3 mm strip of Matrigel from general suture, B4: Fourth 3 mm strip of Matrigel from general 
suture, B5: The first 3 mm strip of Matrigel from NaBu Ultrabraid suture, B6: Second 3 mm strip of Matrigel 
from SB Ultrabraid suture, B7: Third 3 mm strip of Matrigel from SB Ultrabraid suture, B8: Fourth 3 mm strip 
of Matrigel from NaBu Ultrabraid suture. (C) shows relative release of NaBu from the suture into carefully 
processed 3 mm strips of matrigel alone (blue) or in the presence of BAEC (orange) moving away from the 
suture after 24 h. All experiment were repeated at least twice and representative examples are shown.
www.nature.com/scientificreports/
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over the first 24–72 h. Hence, we needed to identify what effects if any this level of release would have on EC/
BAEC activation and angiogenesis.
Our in vitro angiogenesis studies revealed that sodium butyrate at concentrations of between 25 ng/ml and 
5 μ g/ml were strongly angiogenic to vascular endothelial cells, stimulating migration, tube-like-structure formation 
and invasion from one layer of MatrigelTM gel to another. Although we have not detected in the literature previously 
published evidence of butyrate promoting angiogenesis in vitro, recent evidence has suggested a beneficial role on 
tissue remodelling in vivo. Combination treatment of dimethyloxalglycine and butyrate improved bone regenera-
tion and angiogenesis concomitant with increasing expression levels of VEGF in a rat model41 whilst Chen Y. et al.42 
showed that the presence of butyrate increased angiogenesis in diabetic rat hearts, also inhibiting cardiac hypertro-
phy. It would appear the micro-environmental concentration of sodium butyrate within the tissue might determine 
its biological activity as we also showed that concentrations above 10 μ g/ml were not able any more to stimulate 
angiogenesis in vitro. As an anti-cancer agent, in vitro studies have suggested inhibition of growth at concentrations 
of 1 μ g/ml and above-e.g. inhibiting neuroblastoma cell growth, inducing apoptosis and reducing VEGF production 
by the tumour cells43. Hence the effects on cells may be cell-specific. This data strongly support a positive role for 
the Ultrabraid+NaBu suture in supporting angiogenesis and positive tissue remodelling in tendon-bone healing.
We investigation of the signalling mechanism through which sodium butyrate induced angiogenesis by firstly 
conducting a targetted Kinexus phospho-protein microarray after 10 minutes and 1 h exposure to 1 μ g/ml. The 
results indicated increased expression of several proteins linked to angiogenesis, most interestingly, VEGFR2, 
PKCβ 1, PLC-ɣ 1 and FAK. The strong up-regulation of these phosphorylated proteins was confirmed by Western 
blotting. Angiogenesis stimulated through VEGFR2-PLC-PKC and ERK1/244 and concomitantly VEGFR2-FAK45 
are conventional/common signalling mechanisms. Here, we showed that blocking of the VEGFR2 directly with 
inhibiting antibodies, prevented sodium butyrate-induced angiogenesis and in addition, the PKCβ 1 specific 
inhibitor-ruboxistaurin46 produced similar effects without affecting FGF-2 – induced signalling and angiogenesis. 
The most likely explanation for these results is that sodium butyrate was able to stimulate increased production of 
growth factors such as VEGF and this has been demonstrated recently by38, who showed that butyrate treatment of 
rats following middle cerebral artery occlusion, resulted in significant increase in VEGF expression in the ischaemic 
striatum. Our FGF-2 control samples also stimulated phosphorylation of the VEGFR2-as shown in our Western blot-
ting studies, and this autocrine stimulation of VEGF has been reported several times previously within the literature47.
In vivo, we conducted a sponge implant study to test the impact of sodium butyrate. This model has been 
adopted as a model for the accurate quantification of angiogenic and fibrogenic responses as they occur during 
wound healing in vivo. The macroscopic examination of the sponge matrix showed that sodium butyrate induced 
Figure 5. Western blotting shows that phosphorylated proteins, identified from the Kinexus phospho-
protein screen were up-regulated by NaBu. (A) Western blot confirms the phosphorylation of PKCβ 1, FAK, 
ERK1/2, p-VEGFR2 and NFkβ from the samples used in the Kinexus phospho-protein assay after 10/60 minutes 
exposure to NaBu 1 μ g/ml. The bar charts (B) shows the relative intensity of the protein compared with control 
(1.0) expressions. (C) indicates the phosphorylated proteins in additional time-pointed (10–60 minute) sodium 
butyrate treated BAEC. All experiment were repeated at least twice and representative examples are shown.
www.nature.com/scientificreports/
1 1Scientific RepoRts | 6:34649 | DOI: 10.1038/srep34649
Figure 6. NaBu induced tube formation was inhibited in the presence of inhibitors of PKCβ and VEGFR2. 
(A) Shows the NaBu signalling pathway was blocked by the specific PKC inhibitor (Ruboxistaurin; 0.2 μ M), 
and (C) shows the NaBu effect was inhibited by VEGFR2 blocking antibody (ABS553). Note that FGF-2 also 
stimulated phosphorylation of the VEGFR2, however this was not notably inhibited after pre-incubation with 
blocking antibody (see Discussion for explanation). (E,F) Shows strong inhibition of PKCβ 1 phosphorylation 
induced by NaBu and a much weaker inhibition of FGF-2-induced PKC. G and H show the specificity of the 
PKCβ 1 inhibitor as it did not inhibit mCRP-induced phosphorylation of p-ERK1/2 (a) down-stream signalling 
intermediate of the mitogenic pathway). All experiment were repeated at least twice and representative 
examples are shown.
www.nature.com/scientificreports/
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Figure 7. Haemoglobin analysis after 7 days sponge implantation with NaBu. The macroscopic examination 
of the sponge matrix showed that sodium butyrate induced vascularization and blood vessels within the 
implants, as seen in the representative images of the sponges delivered subcutaneously (D). This alteration was 
further confirmed in parts by increase in the haemoglobin content (vascular index) in the sponge implants 
treated with 0.5–1.0 μ g of sodium butyrate and vessels number showed by histological sections treated with 0.1 
and 1.0 μ g. (A) Implant pictures-macroscopic examples. (B) NaBu -soaked implants after 7 days. (D1): Sponge 
only, (D2): Sponge + general suture, (D3): Sponge + NaBu Ultrabraid suture. (D4): no suture and no sponge. All 
experiment were repeated at least twice and representative examples are shown.
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vascularization and blood vessels within the implants, as seen in the representative images of the sponges deliv-
ered subcutaneously. This alteration was further confirmed in parts by increase in the haemoglobin content 
(vascular index) in the sponge implants treated with 0.5–1.0 μ g of sodium butyrate and vessels number showed 
by histological sections treated with 0.1 and 1.0 μ g. This data taken together providing in vivo evidence that low 
concentrations of NaBu induced angiogenesis in mice. Our data are consistent, also, with other in vivo studies 
demonstrated that NaBu was associated with enhanced angiogenesis in models of repair and healing of tendons/
meniscus and in an in vivo model of local cerebral ischemia concomitant with upregulation of VEGF38,40,48,49.
In order to know what would be the promoter of the angiogenic process induced by NaBu in sponge implant 
model, we evaluated the levels of VEGF, which we hypothesise may be primarily responsible for eliciting these 
effects. It has been reported that VEGF levels occur to a greater extent and more consistently than other angio-
genic factors in angiogenesis in vivo models and in our study the VEGF levels was significantly increased when 
treated with 10 μ g sodium butyrate but not in lower concentrations. It is possible that higher VEGF levels in the 
least vascularized implants (10 μ g sodium butyrate treatment) would be a compensatory mechanism to stimulate 
blood vessel formation in the environment of the implants. Furthermore, we suggest that other signalling mecha-
nisms could be influencing the angiogenic process in implants treated with low doses of VEGF.
In this work, we wanted to provide a rationale for the observed improvement seen in tendon-bone healing 
with concomitant histological evidence of better vascular networking and improved tissue remodelling48. Using 
the butyrate-soaked suture in comparison with standard suture, we showed that the Ultrabraid + NaBu suture was 
able to induce substantial endothelial tube-like-structure formation in matrigel in the local micro-environment 
up to approximately 1cm distant from the edge of the suture. No angiogenic effect was seen with standard suture. 
In addition, quantification of the amount of sodium butyrate released showed that it was of the order of magni-
tude that might coincide with in vivo stimulation of tissue remodelling.
Overall, NaBu has been shown to stimulate angiogenesis at low doses in a vascular repair model in vivo and 
any detected pro-angiogenic changes demonstrates the potential of this compound to stimulate repair in a wound 
healing at a site where vasculature is low and healing is compromised.
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